PEGENZILEUKIN
Sponsors
Synthorx Inc., Sanofi-Aventis Recherche & Developpement, Sanofi
Conditions
CancerPlasma Cell Myeloma Refractory
Phase 1
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
RecruitingNCT04643002
Start: 2021-01-25End: 2028-04-20Target: 258Updated: 2026-03-30
An open-label, multicenter Phase 1/2 dose escalation and expansion study of THOR-707 as a single agent and as a combination therapy in adult subjects with advanced or metastatic solid tumors
CompletedCTIS2023-508422-95-00
Start: 2023-05-25End: 2025-12-02Target: 31Updated: 2025-11-13
Phase 1/2 trial evaluating isatuximab in combination with pegenzileukin in relapsed or refractory multiple myeloma (RRMM) previously exposed to anti-CD38 and anti-BCMA
CompletedCTIS2024-514990-23-00
Start: 2021-03-31End: 2025-09-05Target: 27Updated: 2025-11-05